Repare Therapeutics Inc.
RPTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.05 | 0.02 | -0.06 | 0.03 |
| FCF Yield | 3.51% | -27.39% | -69.38% | -49.18% |
| EV / EBITDA | 2.77 | 0.39 | 1.54 | 0.97 |
| Quality | ||||
| ROIC | 1.02% | -16.25% | -24.97% | -20.13% |
| Gross Margin | 0.00% | 100.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.81 | 0.98 | 0.97 | 0.95 |
| Growth | ||||
| Revenue 3-Year CAGR | -40.48% | -88.55% | -80.15% | -25.97% |
| Free Cash Flow Growth | 116.22% | 43.91% | -6.62% | 10.53% |
| Safety | ||||
| Net Debt / EBITDA | -64.09 | 3.52 | 3.11 | 2.95 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 4,914.31 | -173.32 | -4.18 |